JACOBSON PHARMA CORPORATION LIMITED Delivering Health As A Trusted Partner
CONTENTS
2
Corporate Information
3
Financial Highlights
4
Corporate Vision and Mission
5
Corporate Profile
6
Management Discussion and Analysis
18
Other Information
24
Review Report to the Board of Directors
25
Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income
26
Unaudited Consolidated Statement of Financial Position
27
Unaudited Consolidated Statement of Changes in Equity
28
Unaudited Condensed Consolidated Cash Flow Statement
29
Notes to the Unaudited Interim Financial Report
43
Glossary
CORPORATE INFORMATION
BOARD OF DIRECTORS
Executive Directors
Mr. Sum Kwong Yip, Derek
(Chairman and Chief Executive Officer)
Mr. Yim Chun Leung
Ms. Pun Yue Wai
Non-executive Director
Professor Wong Chi Kei, Ian
Independent Non-executive Directors
Dr. Lam Kwing Tong, Alan
Mr. Young Chun Man, Kenneth Professor Lam Sing Kwong, Simon
AUDIT COMMITTEE
Mr. Young Chun Man, Kenneth (Chairman) Dr. Lam Kwing Tong, Alan Professor Lam Sing Kwong, Simon
REMUNERATION COMMITTEE
Dr. Lam Kwing Tong, Alan (Chairman)
Mr. Young Chun Man, Kenneth
Ms. Pun Yue Wai
NOMINATION COMMITTEE
Mr. Young Chun Man, Kenneth (Chairman)
Dr. Lam Kwing Tong, Alan
Mr. Yim Chun Leung
EXECUTIVE COMMITTEE
Mr. Sum Kwong Yip, Derek (Chairman)
Mr. Yim Chun Leung
Ms. Pun Yue Wai
ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE
Professor Lam Sing Kwong, Simon (Chairman)
Mr. Yim Chun Leung
Mr. Yu Chun Kau
HONG KONG HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS
Unit 2313-18, 23/F
Tower 1, Millennium City 1
388 Kwun Tong Road
Kwun Tong, Kowloon
Hong Kong
PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE
Conyers Trust Company (Cayman) Limited
Cricket Square
Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands
HONG KONG BRANCH SHARE REGISTRAR
Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong
AUDITOR
KPMG
Certified Public Accountant
Public Interest Entity Auditor registered in accordance with
the Accounting and Financial Reporting Council Ordinance
PRINCIPAL BANKERS
(in alphabetical order) Chong Hing Bank Limited Standard Chartered Bank (Hong Kong) Limited
The Hongkong and Shanghai Banking Corporation Limited
AUTHORISED REPRESENTATIVES | PUBLIC RELATIONS CONSULTANT |
Strategic Public Relations Group | |
Mr. Yim Chun Leung | |
Ms. Pun Yue Wai | INVESTOR RELATIONS |
COMPANY SECRETARY | Email: jacobsonpharma@sprg.com.hk |
Mr. Yu Chun Kau | STOCK CODE |
REGISTERED OFFICE | 2633 |
Cricket Square | COMPANY WEBSITE |
Hutchins Drive | www.jacobsonpharma.com |
PO Box 2681 | |
Grand Cayman KY1-1111 | |
Cayman Islands |
003
FINANCIAL HIGHLIGHTS
Six months ended | Six months ended | ||
30 September 2022 | 30 September 2021 | Change | |
HK$'000 | HK$'000 | ||
Revenue | |||
- Generic drugs | 581,891 | 562,177 | +3.5% |
- Branded healthcare | 235,462 | 188,236 | +25.09% |
Total | 817,353 | 750,413 | +8.92% |
Gross profit | 340,429 | 272,842 | +24.77% |
Gross profit margin (%) | 41.7% | 36.4% | |
Profit attributable to equity shareholders of the Company | 136,192 | 80,039 | +70.16% |
Profit margin attributable to equity shareholders of the Company (%) | 16.7% | 10.7% | |
Adjusted EBITDA(1) | 290,457 | 203,856 | +42.48% |
Adjusted EBITDA margin (%)(2) | 35.5% | 27.2% | |
Return on equity (%)(3) | 9.9% | 5.8% | |
As at | As at | ||
30 September 2022 | 31 March 2022 | Change | |
HK$'000 | HK$'000 | ||
Total assets | 5,055,953 | 4,755,540 | +6.95% |
Total liabilities | 2,051,768 | 1,797,575 | +14.14% |
Total equity | 3,004,185 | 2,957,965 | +2.59% |
- Adjusted EBITDA is calculated based on adjusted earnings before interest, taxes, depreciation and amortisation, where "interest" is regarded as including interest income and interest expenses and "depreciation and amortisation" is regarded as including impairment losses on non- current assets. To arrive at adjusted EBITDA, the Group's earnings are further adjusted for share of losses of associates, share of losses of joint ventures and non-recurring items not attributable to the operations of individual segments.
- Adjusted EBITDA margin is calculated based on adjusted EBITDA divided by revenue and multiplied by 100%.
- Return on equity is calculated based on annualised profit for the period divided by the arithmetic mean of the opening and closing balances of total equity in the relevant period and multiplied by 100%.
Creating | |
JACOBSON PHARMA CORPORATION LIMITED | INTERIM REPORT 2022 | Values |
004
CORPORATE VISION AND MISSION
A MISSION | A VISION | A CULTURE |
THAT | THAT | THAT |
MATTERS | INSPIRES | ACHIEVES |
OUR VISION
At Jacobson, we aspire to be an eminent player in essential medicines, specialty drugs and consumer healthcare solutions in Greater China and Asia.
OUR CULTURE
Three core components i.e. Challenge, Connect, Commit unite our corporate culture and values that define how we act and what we do:
OUR MISSION
We strive to create sustainable values that meet current and future customer needs through carefully-orchestrated investment in R&D.
We enhance the communities in which we operate.
We build shareholder values in all we do.
CHALLENGE
We proactively venture into uncharted turf for exploring opportunities. We go the extra-mile for attaining excellence via innovative solutions.
CONNECT
We work cohesively as "one company one team" to create and share best practices. We connect local knowledge with global resources.
COMMIT
We deliver on what we promise. We do not compromise on quality and integrity.
JACOBSON PHARMA CORPORATION LIMITED
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Jacobson Pharma Corporation Ltd. published this content on 09 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 December 2022 10:15:02 UTC.
